Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : RNAi -- Ignore unavailable to you. Want to Upgrade?

To: Thomas who wrote (106)	10/2/2003 7:34:26 AM
From: Thomas	Respond to of 671

Hypeware? Pink sheet company gets into the siRNA business (courtesy of Google alerts- incidentally, you would not believe how many people have siRNA as a last name). Any thoughts on this. Sounds fishy to me. Cheers, Thomas CalbaTech to Acquire Molecula Research Laboratories, LLC, a Leading Company in Gene Silencing Technologies for Gene and Protein Function Studies Wednesday October 1, 8:15 am ET IRVINE, Calif., Oct. 1 /PRNewswire-FirstCall/ -- CalbaTech, Inc. (OTC Bulletin Board: CLBE - News), which is focused on acquiring, incubating and developing early stage life science companies, today announced that it has executed an agreement to acquire Molecula Research Laboratories, LLC (Molecula), Herndon, Virginia, a leading company in gene silencing technologies for gene and protein function studies. Terms of the transaction were not disclosed. "CalbaTech's acquisition of Molecula, a private company, allows us to move forward with our strategic plan for the RNAi market," said Matt Maupin, CEO of Molecula. The Company's technology permits delivery of active siRNA or antisense to target genes with a high rate of success. Design technology and experience are some of Molecula's strengths. Even before gene silencing with siRNA became common, Molecula was able to provide to its customers very specific antisense oligos. "We have been in the gene silencing business for ten years with our antisense design technology and believe that we can provide a superior product to researchers exceeding current alternatives," Maupin said. "We understand the complexities of designing one isoform siRNA. The race by companies to design siRNA sequences to every gene is extremely concerning to us because most of the companies are not taking into account all of the possible variables in their siRNA design which can cause non-specific effects, which is not good for researchers." Molecula plans on offering a comprehensive RNAi portfolio, and is in discussions with major international partners to provide its RNAi products worldwide. Molecula also sells transfection reagents, The Inducer(TM) -- a novel IPTG replacement for increased protein expression, neuropeptides and biochemicals. Matt Maupin will continue to serve as CEO of Molecula. "We are delighted to finalize our acquisition of Molecula," said James DeOlden, CEO of CalbaTech. "I am very impressed by the foundation Molecula has established, and we are looking forward to assisting in its growth." CalbaTech is focused on life science based companies, both in the United States and the United Kingdom, in selected synergistic sectors, including Bio-Informatics, Bio-Security and Platform Reagents. CalbaTech is focused on products or technologies that will generate sales or licensing revenue in less than two years, and that will require less than one million dollars to bring the product to market. Additional information can be obtained at the Company's Website at: www.CalbaTech.com. Note: Certain statements in this news release may contain "forward-looking" information within the meaning of rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Act of 1934 and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, may include forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will be accurate and actual results and future events could differ materially from those anticipated in such statements. -------------------------------------------------------------------------------- Source: CalbaTech, Inc.